Thomas Leist, MD and Darin Okuda, MD provide insight into first-line treatment selection for MS and the patient factors involved. Maria Lopes, MD, MS discusses payer considerations and challenges in ...

Multiple sclerosis (MS) is a chronic disease of the central nervous system. MS disrupts the flow of information between the ...

Roche has shared the numbers behind its phase 3 win in primary progressive multiple sclerosis (PPMS), linking its BTK ...

A retrospective chart review of pediatric patients with MS at a tertiary treatment center showed how the center’s first ...

In a study, blocking the immune system complement protein C3 was shown to reduce MS disease severity in older mice but not in ...

OMAHA, Neb. (WOWT/Gray News) - A Nebraska woman has become the first patient in the world to undergo a groundbreaking new treatment for multiple sclerosis. Seven years ago, Jan Janisch-Hanzlik began ...

Should multiple sclerosis (MS) patients stop disease-modifying treatment (DMT) as they get older? The answer depends on several factors, noted John Corboy, MD, of the Rocky Mountain MS Center at the ...

Panelists discuss how payers can evaluate BTK inhibitors by considering specific MS phenotypes and FDA indications rather than applying traditional step therapy protocols that may delay optimal ...

Multiple sclerosis (MS) is a chronic disease of the nervous system that can lead to muscle weakness, vision loss, and paralysis. It occurs when the immune system attacks the myelin sheath that ...

Appealing an insurance claim denial with multiple sclerosis often requires following the rules and being persistent.

PARIS — The first real guidelines on the use of disease-modifying therapies in multiple sclerosis (MS) have been released by a European joint venture between the European Committee for Research and ...